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Background
Utilizing tumors as a source of vaccine antigens in immu-
notherapy has demonstrated promising results. However,
to date, researchers have failed to overcome the complex
interplay between the tumor and its surrounding microen-
vironment resulting in T cell tolerance. The progression
to a productive immune response involves a number of
immunological checkpoints to be passed. Checkpoints
such as CTLA-4 and PD-1 are use to dampen or terminate
immune responses, which act as barriers to immunothera-
pies targeting malignant self-cells that express similar sur-
face antigens as the cells which they derive. To overcome
this limitation, the FDA approved three checkpoint inhibi-
tors ipilumimab, pembrolizumab and nivolumab.
Methods
In our glioma model, we discovered an excess of soluble
CD200 protein in the cerebral spinal fluid and cervical
lymph nodes, which acts as a checkpoint blockade.
CD200 is highly expressed in a variety of human tumors
including melanoma and glioblastomas. There are multi-
ple checkpoints blockades including CD200.
Results
We determinerd that CD200/CD200R interactions upregu-
late peptidylprolyl isomerase A (PPIA) inhibiting the pro-
duction of TNF-a and IL-2, induces the formation of
myeloid derived suppressor cells (MDSC) and tolergenic
antigen presenting cells. We developed a competitive inhi-
bitor of CD200 capable of overcoming CD200 induced
suppression. Preliminary data show that these inhibitor
peptides inhibit PPIA production and the differentiation of
MDSC’s, induce lymphocyte infiltration into site of vacci-
nation, upregulate MHC-II and co-stimulatory molecules
enhances immunogenicity resulting in a significant survival
benefit in our glioma and breast tumor models. Moreover,
the use of our inhibitor in our canine spontaneous glioma
model resulted in tumor regression and lymphocyte infil-
tration into the tumor site in our patients. Recently,
we developed human candidate peptides for translation to
the clinic. Our preliminary data showed that pulsing
monocyte derived immature dendritic cells up-regulated
MHC-II and CD86 and enhanced IL-12, TNF-b, and che-
mokine’s Rantes, CXCL8, CXCL9 and CXCL10 secretion.
Conclusions
This study has major implications for the design of trans-
lational research approaches and future clinical trials. The
proposed study is designed to elucidate and overcome the
mechanism of tumor-induced immunosuppression. If our
hypothesis is correct, the use of a competitive inhibitor
may overcome the suppressive properties of the tumor in
both the sentinel lymph nodes as well within the tumor
microenvironment ultimately leading to the development
of novel therapeutics that increase the efficacy of cancer
immunotherapy.
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